Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Visualization of myelination in GFP-transgenic zebrafish.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
UCSF Seminar: "Antibody Repertoire Sequencing"
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Dilantin
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
RTL therapy for multiple sclerosis: a Phase I clinical study.

Pages